We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Norovirus Assays Compared In Acute Gastroenteritis Patients

By LabMedica International staff writers
Posted on 24 May 2016
Print article
Image: The Xpert Norovirus assay cartridge (Photo courtesy of Cepheid).
Image: The Xpert Norovirus assay cartridge (Photo courtesy of Cepheid).
Noroviruses (NoVs) are the most common cause of acute viral gastroenteritis worldwide and they affect all age group and are frequently involved in outbreaks in communal facilities, such as hospitals, schools, prisons, cruise ships.

Norovirus infections mainly cause nausea, vomiting, diarrhea and fever, the symptoms are generally of a relatively short duration and they usually resolve within 2 to 6 days. The virus affects approximately 267 million people and causes over 200,000 deaths each year. NoVs include six distinct genogroups, and NoV GI and GII are the most frequently detected in human infections, while NoV GIV is also implicated in human gastroenteritis.

Scientists at the Fondazione IRCCS Policlinico San Matteo (Pavia, Italy) and their colleagues collected 173 stool samples during the period February 2012 to April 2014 from 173 adult patients hospitalized with acute gastrointestinal syndromes, patient age ranged from 29 years to 101 years (median age 79 years). Acute gastroenteritis was defined as the rapid onset of two or more of the following symptoms: diarrhea, vomiting, nausea, fever or abdominal pain.185 (5)

The stool samples were tested in parallel with a laboratory developed (LD) real-time reverse transcription-polymerase chain reaction (RT-PCR) assay and with Xpert Norovirus Assay (Cepheid, Sunnyvale, CA, USA). Both the LD real-time RT-PCR assays and the new molecular “on demand” test Xpert Norovirus Assay are designed to detect NoV GI and GII. Stored archival samples volumes were tested with two specific NoV real-time RT PCR assays, one targeting a portion of NoV GI capsid gene and the other targeting a portion of NoV GII ORF1-ORF2 junction gene.

When the scientists used the Xpert Norovirus Assay, 62/173 (36.0%) samples were positive: one for NoV GI and 61 for NoV GII, while 111/173 (64.0%) samples were negative. The laboratory real-time RT-PCR assays detected NoV in 65/173 (37.5%) samples: one NoV GI and 64 NoV GII, while 108/173 (62.5%) were negative. The Xpert Norovirus Assay results were concordant with results obtained using LD real time RT-PCR in 62/65 (95.4%) samples tested, while in 3/65 (4.6%) samples were discordant.

The authors concluded that the Xpert Norovirus Assay results could be obtained in 90 minutes and with a simpler sample handling. The LD NoV real-time RT-PCR assays has an high sensitivity and includes two separated steps, extraction and amplification, thus requiring more time to get the results, but it is less expensive than the commercial assay. In conclusion, high-level concordance (95.4%) was observed between Xpert Norovirus Assay and the LD real-time RT-PCR assays. The study was published online on May 4, 2016, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Fondazione IRCCS Policlinico San Matteo
Cepheid
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.